@article{ATM10304,
author = {Yuki Owada and Satoshi Muto and Takeo Hasegawa and Mitsunori Higuchi and Hiroyuki Suzuki},
title = {Revisiting of cancer vaccine?—specific immunotherapy comes to field with the biomarker},
journal = {Annals of Translational Medicine},
volume = {4},
number = {9},
year = {2016},
keywords = {},
abstract = {Coley et al., advocated a hypothesis of immune response against malignant tumors and he applied his concept by providing patients with the first cancer immunotherapy in 1906 (1). A few decades later, Bacillus Calmette-Guerin was introduced as a tumor immunotherapy by Old et al. (2). These non-specific immunotherapies have been promising cancer therapies, however, they were not widely accepted because of the unstable efficacy and a lack of understanding of the mechanisms of action. After understanding tumor-associated antigens and after discovering dendritic cells, the cancer immunotherapies primarily studied were specific cancer immunotherapies, such as cancer vaccines and dendritic cell vaccines.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/10304}
}